Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (141-150 of 515) with videos related to

Pageof 52
Sort By:
American Journal of Hematology|July 24, 2010
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cellsVijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, et al.
Journal of Blood Medicine|September 2, 2017
New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomibPaul G Richardson, Shaji Kumar, Jacob P Laubach, et al.
Leukemia & Lymphoma|October 7, 2014
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agentsMorie A Gertz, Evangelos Terpos, Angela Dispenzieri, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 12, 2010
Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition diseaseElizabeth C Lorenz, Sanjeev Sethi, Tanya L Poshusta, et al.
Blood|October 22, 2024
Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detectionAlissa Visram, Dirk Larson, Aaron Norman, et al.
Blood Cancer Journal|May 19, 2019
Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathiesShaji Kumar, Dirk R Larson, Angela Dispenzieri, et al.
Future Oncology (London, England)|April 3, 2015
The investigational proteasome inhibitor ixazomib for the treatment of multiple myelomaPaul G Richardson, Philippe Moreau, Jacob P Laubach, et al.
Cancer Cell International|August 29, 2020
Epigenetic silencing of long non-coding RNA <i>BM742401</i> in multiple myeloma: impact on prognosis and myeloma disseminationZhenhai Li, Shaji Kumar, Dong-Yan Jin, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2013
Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemiaRobert A Kyle, Terry M Therneau, Angela Dispenzieri, et al.
Cancer|October 10, 2013
Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategiesBrian L Burnette, Angela Dispenzieri, Shaji Kumar, et al.
Pageof 52

Showing results (141-150 of 515) with videos related to

Sort By:
Pageof 52
American Journal of Hematology|July 24, 2010
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cellsVijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, et al.
Journal of Blood Medicine|September 2, 2017
New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomibPaul G Richardson, Shaji Kumar, Jacob P Laubach, et al.
Leukemia & Lymphoma|October 7, 2014
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agentsMorie A Gertz, Evangelos Terpos, Angela Dispenzieri, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 12, 2010
Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition diseaseElizabeth C Lorenz, Sanjeev Sethi, Tanya L Poshusta, et al.
Blood|October 22, 2024
Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detectionAlissa Visram, Dirk Larson, Aaron Norman, et al.
Blood Cancer Journal|May 19, 2019
Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathiesShaji Kumar, Dirk R Larson, Angela Dispenzieri, et al.
Future Oncology (London, England)|April 3, 2015
The investigational proteasome inhibitor ixazomib for the treatment of multiple myelomaPaul G Richardson, Philippe Moreau, Jacob P Laubach, et al.
Cancer Cell International|August 29, 2020
Epigenetic silencing of long non-coding RNA <i>BM742401</i> in multiple myeloma: impact on prognosis and myeloma disseminationZhenhai Li, Shaji Kumar, Dong-Yan Jin, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2013
Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemiaRobert A Kyle, Terry M Therneau, Angela Dispenzieri, et al.
Cancer|October 10, 2013
Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategiesBrian L Burnette, Angela Dispenzieri, Shaji Kumar, et al.
Pageof 52